Published in Hepatitis Weekly, September 16th, 1996
George Marinos and colleagues further noted that these variants always coexist with the wild-type hepatitis B virus (HBV), and that the presence of core gene deletion variants does not confer resistance to interferon-alpha (IFN-(alpha)) treatment.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.